

Siemens Healthineers gives details on second phase of Strategy 2025 and on the further development of its businesses

At a capital markets event in London, the management of Siemens Healthineers AG will provide further details on the second phase of its "Strategy 2025". This so-called "Upgrading" phase is about taking Siemens Healthineers to the next level of profitable growth. As already communicated, the company aims to achieve revenue growth on a comparable basis, i.e. excluding currency translation and portfolio effects, of five to six percent in fiscal year 2020 (ending September 30), with adjusted¹ basic earnings per share rising six to twelve percent over the previous year. In fiscal years 2021 and 2022, revenue is expected to grow by more than five percent each year on a comparable basis, and adjusted basic earnings per share should record an annual increase of around ten percent.

"The healthcare system worldwide is in a state of upheaval. Cost pressure and consolidation on the customer side as well as far-reaching digitalization are key trends in the coming years. Thanks to our strong technological base, extensive clinical expertise and our global network, we can help make healthcare more efficient and further improve access to healthcare. At the same time, our digital and AI-based offerings put us in a unique position to play a decisive role in the key areas of the healthcare market. During the Upgrading phase, we will continue to grow in existing markets, enter adjacent fields and make new markets", said Bernd Montag, CEO of Siemens Healthineers AG.

Siemens Healthineers has defined clear priorities during the Upgrading phase for its three segments. In the Imaging segment, the focus is on continuously innovating the core business, expanding its diagnostic offerings as well as on taking a leading role in supporting clinical decision-making based on artificial intelligence. In the Diagnostics segment, the

¹ Adjusted for amortization of intangible assets acquired in business combinations, severance charges and acquisition-related transaction costs, net of tax

main task is to exploit the opportunities arising from the market trend towards automated workflows in laboratory diagnostics. On top of this, it is planned to further expand the point-of-care business. One focus of the Advanced Therapies segment is on combining the technologies of the robotics company Corindus Vascular Robotics, which was acquired in October, with the existing portfolio to achieve additional growth and make new markets.

The plans of the segments will be supplemented by three company-wide priorities: market share gains in geographic growth markets as well as with leading healthcare providers, and the further acceleration of the company's digital transformation.

The company completed the first phase of the "Siemens Healthineers Strategy 2025" at the end of fiscal year 2019. During this phase, Siemens Healthineers successfully implemented its IPO and launched important product innovations such as the AI Companions. With the acquisitions of Corindus and the U.S.-based consulting firm ECG Management Consultants, the company has recently strengthened its offerings in adjacent growth areas.

This press release can be found at:

<https://www.siemens-healthineers.com/press-room/press-releases/pr-meet-the-management-2019.html>

Contact for journalists

Stefan Schmidt

Phone: +49 152 02307361 E-mail: stefansschmidt@siemens-healthineers.com

Philipp Grontzki

Phone: +49 152 03350194; E-mail: philipp.grontzki@siemens-healthineers.com

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion. Further information is available at www.siemens-healthineers.com.

This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as "expect", "forecast", "anticipate", "intend", "plan", "believe", "seek", "estimate", "will", "target" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers' management, of which many are beyond Siemens Healthineers' control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer. The information contained in this document is provided as of the date of its publication and is subject to change without notice.